Final analysis of phase 3 COSMIC-313 in untreated advanced RCC: adding cabozantinib to nivolumab-ipilimumab lengthened median PFS (16.6 vs 11.2 months; HR 0.82) but not OS (HR 1.02); grade 3/4 treatment-related AEs were 75% vs 43%.
RCT
Motzer et al. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study